Abstract
Active surveillance for small renal masses (SRMs) is an accepted management strategy for patients with prohibitive surgical risk. Emerging prospectively collected data support the concept that a period of initial active surveillance in an adherent patient population with well-defined criteria for delayed intervention is safe. This article summarizes the literature describing growth kinetics of SRMs managed initially with observation and oncologic outcomes for patients managed with active surveillance. Existing clinical tools to determine and contextualize competing risks to mortality are explored. Finally, current prospective clinical trials with defined eligibility criteria, surveillance schema, and triggers for delayed intervention are highlighted.
Original language | English |
---|---|
Pages (from-to) | 213-222 |
Number of pages | 10 |
Journal | Urologic Clinics of North America |
Volume | 44 |
Issue number | 2 |
DOIs | |
State | Published - May 2017 |
Keywords
- Active surveillance
- Growth kinetics
- Kidney cancer
- Outcomes
- Small renal mass